Law firms Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia · 28 April 2014 · 2 min read Corporate and M&A Davis Polk Freshfields Skadden, Arps, Slate, Meagher & Flom Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categorySports is the new private capital frontier – why top firms are upping their gameLaw firmsMatthias Bergg14 Aug 2026Slaughters and Freshfields in line for over £25m in fees from Rotork-ABB dealLaw firmsKate Peacock7 Aug 2026The $400bn AstraZeneca mega-merger: which firms could land the mandate?Law firmsEliza Winter5 Aug 2026US trio lead on multibillion-dollar Stripe-OpenRouter dealLaw firmsKate Peacock20 Aug 2026International trio serve up as BuzzBallz owner Sazerac buys Au Vodka for £500mLaw firmsEliza Winter18 Aug 2026Latham, A&O Shearman and CC up front as Jeff Bezos-backed consortium buys stake in Liverpool FCLaw firmsKate Peacock14 Aug 2026Revolving doors: Simpson Thacher, Latham, Sidley lead New Year London movesLaw firmsAnna Huntley9 Jan 2025Five partners vie to succeed Hoyland as Simmons managing partnerLaw firmsTom Cox7 Jan 2025‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetryLaw firmsAnna Huntley7 Jan 2025